Advanced Ovarian Cancer

Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.

Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.

LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.

The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.

A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.

Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.

New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.

Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.